AIM: To observe the effects of different antidiabetic therapies on macular thickness in diabetes patients without fundus complication.

METHODS: The macular thickness was measured by optical coherence tomography(OCT). The retina volume on the center of macula was scanned, and it generated automatically the average thickness data of three rings and nine areas of 1mm, 3mm and 6mm. The data were statistically analyzed.

RESULTS: Healthy control group, oral hypoglycemic drug group and insulin treatment group were enrolled. Each group included 22 cases 22 eyes. The macular retinal thickness of healthy control group is 268.09±17.97μm(the 1^st ring), 340.41±22.25μm(the 2^nd ring)and 298.14±12.90μm(the 3^rd ring), respectively. The macular thickness of oral hypoglycemic drug group is 260.00±18.17μm(the 1^st ring), 335.44±21.12μm(the 2^nd ring)and 295.63±15.92μm(the 3^rd ring), respectively. The macular thickness of insulin therapy group is 271.01±26.09μm(the 1^st ring), 340.86±17.10μm(the 2^nd ring)and 298.57±12.14μm(the 3^rd ring), respectively. Comparison of the macular thickness of the 1^st ring among 3 groups was insignificant(F=1.21, P=0.31), neither the comparison of the 2^nd ring(F=0.35, P=0.71), neither the comparison of the 3^rd ring(F=0.22, P=0.81).

CONCLUSION: Compared with healthy individuals, both oral antidiabetic medicines and insulin therapy don't alter the macular thickness of patients with diabetes while without fundus complication.